文献速递关节外科

口服与静脉氨甲环酸在全髋关节置换术后减少失血方面等效:一项随机对照试验

Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

这项双盲随机对照试验将89例初次全髋关节置换患者随机分为口服氨甲环酸组(术前2小时口服1.95克)和静脉氨甲环酸组(切皮前静脉推注1克),最终83例纳入分析。口服组与静脉组血红蛋白下降均值分别为3.67 g/dL与3.53 g/dL(等效性p=0.0008),总失血量分别为1339 mL与1301 mL(等效性p=0.034),输血率无显著差异(7.5% vs 2.3%,p=0.35)。

要点

  • 口服氨甲环酸在初次全髋关节置换中减少失血的效果与静脉给药等效。
  • 口服组与静脉组血红蛋白下降分别为3.67 g/dL与3.53 g/dL,等效性检验p=0.0008。
  • 口服组与静脉组总失血量分别为1339 mL与1301 mL,等效性检验p=0.034。

核心结论

  • 口服氨甲环酸在初次全髋关节置换中提供与静脉制剂等效的失血减少,且成本大幅降低。

研究设计与样本

  • 双盲随机对照试验,89例初次全髋关节置换患者随机分组,6例因方案偏离排除,83例纳入分析。
  • 口服组术前2小时口服氨甲环酸1.95克,静脉组切皮前静脉推注氨甲环酸1克。
  • 功效分析确定每组需28例,血红蛋白等效界值为±1.0 g/dL,α=5%,功效80%。
  • 等效性分析采用双单侧检验(TOST),p<0.05表示等效。

主要发现

  • 口服组40例与静脉组43例,两组患者人口学特征相似。
  • 血红蛋白下降均值口服组3.67 g/dL与静脉组3.53 g/dL相比,等效性p=0.0008。
  • 总失血量均值口服组1339 mL与静脉组1301 mL相比,等效性p=0.034。
  • 输血患者口服组3例(7.5%)与静脉组1例(2.3%)相比,差异无统计学意义(p=0.35)。
  • 两组均无患者发生血栓栓塞事件。

关键数值与推荐

  • 口服氨甲环酸剂量为1.95克,术前2小时给药;静脉氨甲环酸剂量为1克,切皮前推注。
  • 血红蛋白等效界值为±1.0 g/dL,等效性检验p<0.05判定为等效。

临床怎么用

  • 口服氨甲环酸可作为静脉制剂的等效替代用于初次全髋关节置换以减少失血,且成本大幅降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid is an antifibrinolytic that has been shown to reduce blood loss and the need for transfusions when administered intravenously in total hip arthroplasty. Oral formulations of the drug are available at a fraction of the cost of the intravenous preparation. The purpose of this randomized controlled trial was to determine if oral and intravenous formulations of tranexamic acid have equivalent blood-sparing properties. METHODS: In this double-blinded trial, 89 patients undergoing primary total hip arthroplasty were randomized to receive 1.95 g of tranexamic acid orally 2 hours preoperatively or a 1-g tranexamic acid intravenous bolus in the operating room prior to incision; 6 patients were eventually excluded for protocol deviations, leaving 83 patients available for study. The primary outcome was the reduction of hemoglobin concentration. Power analysis determined that 28 patients were required in each group with a ±1.0 g/dL hemoglobin equivalence margin between groups with an alpha of 5% and a power of 80%. Equivalence analysis was performed with a two one-sided test (TOST) in which a p value of <0.05 indicated equivalence between treatments. RESULTS: Forty-three patients received intravenous tranexamic acid, and 40 patients received oral tranexamic acid. Patient demographic characteristics were similar between groups, suggesting successful randomization. The mean reduction of hemoglobin was similar between oral and intravenous groups (3.67 g/dL compared with 3.53 g/dL; p = 0.0008, equivalence). Similarly, the mean total blood loss was equivalent between oral and intravenous administration (1,339 mL compared with 1,301 mL; p = 0.034, equivalence). Three patients (7.5%) in the oral group and one patient (2.3%) in the intravenous group were transfused, but the difference was not significant (p = 0.35). None of the patients in either group experienced a thromboembolic event. CONCLUSIONS: Oral tranexamic acid provides equivalent reductions in blood loss in the setting of primary total hip arthroplasty, at a greatly reduced cost, compared with the intravenous formulation. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Kayupov E, Fillingham YA, Okroj K, et al. Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. J Bone Joint Surg Am. 2017. PMID: 28244907. doi:10.2106/JBJS.16.00188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。